eyeonfda (@eyeonfda) profile picture

Author of the blog Eye on FDA - https://xitter.gq/t.co/BWgQ12Mmov

New York, USA
Joined April 2008
Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)Photo by eyeonfda (@eyeonfda)
Wow. @US_FDA skeds first hybrid (half in person) human drugs #AdComm for April - an #ODAC meeting - public-inspection.federalreg…
340
An overview of the third regulatory action letter sent by @US_FDA #OPDP this year - eyeonfda.com/2023/08/fdas-op…
2
1
552
Every six months - a look-back at FDA communications - What They Said - eyeonfda.com/2023/08/what-th…
857
eyeonfda retweeted
Today, FDA approved a tablet for nonprescription use to prevent pregnancy — the first daily oral contraceptive approved for use in the U.S. without a prescription. fda.gov/news-events/press-an…
17
172
64
243
140,598
eyeonfda retweeted
WATCH LIVE: The VRBPAC meeting is underway where the committee will discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign. youtube.com/live/gBOyPREXGh8
9
23
10
29
27,611
Emerging from Emergency - Two COVID-related developments this week and the implications thereof for #pharma and others - ow.ly/6xAk50MH4LH
1
221
What did FDA have to say in 2022 and how did it compare to previous years. There have been some change both in volume and approach. ow.ly/i7Cj50MB03J
212
My overview of #AdComms held last year by @US_FDA compared to previous years - there have been fewer held and they have skewed more negatively. Is it be a difference pre-/post-pandemic? Does the shift to a virtual setting make a difference? eyeonfda.com/2023/01/when-th… #pharma
2
1
294
zacharybrennan: FDA adcomm votes 14-1 to pull Makena - more than a decade after it first won accelerated approval
Tik Tok is another example of how #OPDP needs to update its approach to regulatory oversight of #DTC and #pharma communications - ow.ly/WKUM50Lfnva
4/4 - @US_FDA #OPDP intent to study Targeted Mechanism of Action Presentations in RX Drug Promotion to see how varied targeted MoA presentations affect audience understanding of MoA, perception of benefits/risks, and risk info/interest in the drug- ow.ly/wStk50KQzAi
3/4 - Another @US_FDA #OPDP research effort announced - Perceptions of Prescription Drug Products With Medication Tracking Capabilities - public-inspection.federalreg… #pharma #DTC
1
1
2/4 - One study announced by @US_FDA #OPDP - Endorser Status and Actual Use in #DTC Television Ads - examining the influence of two independent variables--endorser type (patient, physician) and actual-use disclosure - in television ads - public-inspection.federalreg…
1/4 - @US_FDA gives notice of 3 new research efforts related to #pharma promotional communications.
1
After a sleepy year, @US_FDA schedules another #AdComm, this time the #Cardiovascular and Renal Drugs Advisory Committee to discuss NDA for tenapanor hydrochloride tablets for the control of serum phosphorus levels in adults w/ #CKD on dialysis- ow.ly/bPc950KLuvy
A 6-month look-back at what #FDA talked about - it wasn't COVID and it wasn't much about new approvals - ow.ly/wH1h50KlL4O
Here we go again - communications in the challenging environment shaped by an emerging pathogen - this time Monkeypox. Employers, Educators, Service Providers - should maybe start re-thinking content in the face of the new outbreak - ow.ly/JS8750KelRK #monkeypox
1